Vaxart, Inc. (NASDAQ:VXRT) Stock Position Raised by Bank of America Corp DE

Bank of America Corp DE lifted its holdings in shares of Vaxart, Inc. (NASDAQ:VXRT) by 10.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 184,447 shares of the biotechnology company’s stock after buying an additional 17,942 shares during the period. Bank of America Corp DE owned 0.08% of Vaxart worth $122,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Raymond James Financial Inc. bought a new position in Vaxart in the 4th quarter worth about $129,000. Sequoia Financial Advisors LLC grew its position in Vaxart by 140.9% in the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 35,213 shares during the last quarter. Geode Capital Management LLC grew its position in Vaxart by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company’s stock worth $1,723,000 after purchasing an additional 57,911 shares during the last quarter. Invesco Ltd. grew its position in Vaxart by 48.6% in the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 24,803 shares during the last quarter. Finally, Silverarc Capital Management LLC grew its position in Vaxart by 7.8% in the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock worth $714,000 after purchasing an additional 77,782 shares during the last quarter. Institutional investors own 18.05% of the company’s stock.

Insider Activity at Vaxart

In other Vaxart news, insider Steven Lo bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, May 19th. The stock was acquired at an average cost of $0.49 per share, with a total value of $49,000.00. Following the completion of the purchase, the insider now directly owns 100,000 shares in the company, valued at approximately $49,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Vaxart to a “hold” rating in a research report on Thursday, May 22nd. B. Riley decreased their target price on shares of Vaxart from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Thursday, March 27th.

Vaxart Price Performance

Vaxart stock opened at $0.66 on Tuesday. The firm has a 50 day simple moving average of $0.42 and a 200-day simple moving average of $0.55. The stock has a market capitalization of $150.71 million, a PE ratio of -1.61 and a beta of 1.25. Vaxart, Inc. has a 12-month low of $0.29 and a 12-month high of $1.07.

Vaxart (NASDAQ:VXRT) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. On average, analysts forecast that Vaxart, Inc. will post -0.39 earnings per share for the current fiscal year.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.